Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations.

  title={Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations.},
  author={Erik W Anderson and Richard A. Furie},
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is potentially life-threatening and can affect any organ. The complex pathogenesis and heterogeneity of the disease, among other factors, present significant challenges in developing new therapies. Knowledge gained over many years has implicated type I interferon (IFN) in the pathogenesis of SLE and anti-IFN therapies hold promise as a much-needed future treatment for SLE. Anifrolumab, a human monoclonal antibody against… 
A Comprehensive Review of Biological Agents for Lupus: Beyond Single Target
B bispecific antibodies (BsAbs) such as tibulizumab, which simultaneously targets multiple pathogenic cytokines or pathways, may provide a novel therapeutic strategy for SLE.
Type I interferon antagonists in clinical development for lupus
It seems likely that a type I IFN antagonist will come to clinical utility for SLE given the large unmet need and the recent phase III success with anifrolumab.
New era of therapy for endocrine autoimmune disorders
Which new therapies might be used in the different stages of the disease, focus on legalized therapy and elaborate on the ongoing clinical studies for these diseases and the research front, before hypothesizing on the way ahead.
Levels of type I interferon in patients with systemic lupus erythematosus
The results suggest the importance that the determination of IFN type I could have for the monitoring of SLE activity and evaluate its usefulness as a biomarker of activity.
Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects
The identification of multiple immunologic abnormalities in patients with APS reveals molecular targets for current or future treatment and new drugs such as eculizumab and sirolimus seem to be promising drugs for APS.
Interferon α Enhances B Cell Activation Associated With FOXM1 Induction: Potential Novel Therapeutic Strategy for Targeting the Plasmablasts of Systemic Lupus Erythematosus
Microarray analysis of naïve and memory B cells and plasmablasts that were freshly isolated from healthy controls and active SLE revealed that all B cell subsets of SLE expressed more type I IFN-stimulated genes, suggesting that a causative relationship exists between type IIFN priming and enhanced proliferative capacity through FOXM1.
Overcoming Therapy Resistance and Relapse in TNBC: Emerging Technologies to Target Breast Cancer-Associated Fibroblasts
A number of therapeutic candidates are designed to effectively target BCAFs with a focus on their tumor-promoting properties and tumor immune response, including small molecules, nucleic acid-based agents, antibodies, proteins, and finally, nanoparticles.
Inhibition of interferon-signalling halts cancer-associated fibroblast-dependent protection of breast cancer cells from chemotherapy
CAF-induced activation of IFN signalling in claudin-low TNBCs results in chemoresistance, and inhibition of this pathway represents a novel method to improve breast cancer outcomes.
Type I IFN stimulates IFI16-mediated aromatase expression in adipocytes that promotes E2-dependent growth of ER-positive breast cancer
A novel function of type I IFNs is reported in inducing aromatase expression in adipose tissues surrounding BC, which potentiates the E2-dependent growth of estrogen receptor (ER)-positive BC.


Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date
Anifrolumab demonstrated promising results on cutaneous and arthritic manifestations, especially among patients with a high IFN gene signature, and the pivotal Treatment of Uncontrolled Lupus via the Interferon IFN Pathway (TULIP 1 and 2 studies are now completed) showed positive results on the composite primary endpoint SRI-4.
Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
BACKGROUND Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a significant effect on
New insights into the immunopathogenesis of systemic lupus erythematosus
Improved understanding of the pathogenesis of SLE is driving a renewed interest in targeted therapy, and researchers are now on the verge of developing targeted immunotherapy directed at treating either specific organ system involvement or specific subsets of patients with SLE.
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)
In an exploratory analysis, rontalizumab treatment was associated with improvements in disease activity, reduced flares and decreased steroid use in patients with SLE with low ISM scores, and the primary and secondary end points of this trial were not met.
Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C
We present the case of a 53-year-old woman who developed systemic lupus erythematosus (SLE) after being treated with interferon-alpha (IFN-α) for cryoglobulinemic vasculitis associated with hepatitis
Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
Anifrolumab treatment was associated with improvements versus placebo in specific SLE features of arthritis and rash using measures of different stringency, driven by robust data in the prevalent IFNGS test–high population.
Possible induction of systemic lupus erythematosus by interferon‐α treatment in a patient with a malignant carcinoid tumour
Systemic lupus erythematosus after treatment with IFN‐α has not been described, although a majority of SLE patients have demonstrable serum levels of IFN-α, which correlate with disease activity and have been suggested to be of pathogenetic significance.
Type I interferon in rheumatic diseases
The type I interferon pathway has been implicated in the pathogenesis of a number of rheumatic diseases, including systemic lupus erythematosus, Sjögren syndrome, myositis, systemic sclerosis, and